Keywords: cubist, hit, missed, endpoint, cidecin, trial, pharmaceuticals

Cubist hit by missed endpoint in Cidecin trial.

Article | 21 January 2002

Print This

Cubist Pharmaceuticals reported after the close of the markets onJanuary 16 that the first Phase III trial of its investigational antibiotic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in